Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Cell Prolif ; 41(6): 988-1001, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19040574

RESUMO

OBJECTIVES: The ADAMs (a disintegrin and metalloproteinase) enzymes compose a family of membrane-bound proteins characterized by their multi-domain structure and ADAM-12 expression is elevated in human non-small cell lung cancers. The aim of this study was to investigate the roles played by ADAM-12 in critical steps of bronchial cell transformation during carcinogenesis. MATERIALS AND METHODS: To assess the role of ADAM-12 in tumorigenicity, BEAS-2B cells were transfected with a plasmid encoding human full-length ADAM-12 cDNA, and then the effects of ADAM-12 overexpression on cell behaviour were explored. Treatment of clones with heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) neutralizing antibodies as well as an EGFR inhibitor allowed the dissection of mechanisms regulating cell proliferation and apoptosis. RESULTS: Overexpression of ADAM-12 in BEAS-2B cells promoted cell proliferation. ADAM-12 overexpressing clones produced higher quantities of HB-EGF in their culture medium which may rely on membrane-bound HB-EGF shedding by ADAM-12. Targeting HB-EGF activity with a neutralizing antibody abrogated enhanced cell proliferation in the ADAM-12 overexpressing clones. In sharp contrast, targeting of amphiregulin, EGF or transforming growth factor-alpha failed to influence cell proliferation; moreover, ADAM-12 transfectants were resistant to etoposide-induced apoptosis and the use of a neutralizing antibody against HB-EGF activity restored rates of apoptosis to be similar to controls. CONCLUSIONS: ADAM-12 contributes to enhancing HB-EGF shedding from plasma membranes leading to increased cell proliferation and reduced apoptosis in this bronchial epithelial cell line.


Assuntos
Proteínas ADAM/metabolismo , Apoptose , Brônquios/citologia , Células Epiteliais/citologia , Células Epiteliais/enzimologia , Proteínas de Membrana/metabolismo , Proteína ADAM12 , Animais , Linhagem Celular , Movimento Celular , Proliferação de Células , Células Clonais , Fator de Crescimento Semelhante a EGF de Ligação à Heparina , Humanos , Marcação In Situ das Extremidades Cortadas , Injeções Subcutâneas , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Camundongos , Camundongos SCID , Invasividade Neoplásica , Transfecção
2.
Cell Mol Biol (Noisy-le-grand) ; 49(6): 875-84, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14656045

RESUMO

Matrix metalloproteinases (MMPs) are an at least 23 member family of calcium and zinc dependent enzymes implicated in many physiological and pathological processes. Asthma, chronic obstructive pulmonary disease (COPD) and emphysema are diseases associated with an inflammation of the airways and lung parenchyma. In this review, we focus on the role played by MMPs in the pathogenesis of inflammation, airway remodelling and alveolar destruction, depicting the observational studies in humans and the experimental studies in animal models. During the course of asthma, MMP-2,-8,-9 and TIMP-1 are expressed at baseline and the allergen exposure or exacerbations of the disease lead to an increase of MMP-9 secretion being at this time much higher than that of TIMP-1, allowing temporarily a matrix damage, possibly followed by abnormal repair. Animal models suggest a predominant role for MMP-9 and MMP-12 in the pathogenesis of pulmonary inflammation and link an absence of MMP-2 to an increased parenchymal inflammation. In COPD and emphysema, human studies indicate an over-secretion of MMP-2,-8,-9 and animal models pointout MMP-1 and MMP-12 as being key players in the pathogenesis of emphysema. Taken together, these data identify specific MMP inhibition as appropriate target for therapeutic intervention in asthma or COPD/emphysema They also strongly argue against the widespread use of large spectrum non specific inhibitors that could be detrimental.


Assuntos
Asma/enzimologia , Inibidores Enzimáticos/farmacologia , Metaloproteinases da Matriz/fisiologia , Doença Pulmonar Obstrutiva Crônica/enzimologia , Animais , Asma/tratamento farmacológico , Asma/patologia , Enfisema/patologia , Humanos , Inibidores de Metaloproteinases de Matriz , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/patologia , Inibidores Teciduais de Metaloproteinases/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA